An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases.
Interleukin (IL)-1 is a pivotal proinflammatory cytokine consisting of two molecular species, IL-1α and IL-1β. Anakinra (Kineret), a recombinant human IL-1 receptor antagonist, is regarded as a biological agent which blocks the inflammatory effects of IL-1. The aim of this review was to search the literatures and summarizes in vivo, in vitro and human studies on anakinra uses in dermatological disorders. The results show that anakinra is currently used clinically for the treatment of a variety of skin conditions such as psoriasis, atopic dermatitis, photoagaing, melanoma, Schnitzler syndrome, pyoderma gangraenosum, PAPA syndrome, hidradenitis suppurativa, lamellar ichthyosis, Sweet's syndrome, panniculitis, Muckle-Wells syndrome, familial Mediterranean fever, SAPHO syndrome and other disorders. Notably, anakinra is expensive to produce and administer. Injection is the route of therapy and allergic reaction is most possible.
Department of Dermatology, Jundishapur University of Medical Sciences, Ahvaz, Iran.
Nader
N
Pazyar
Amir
A
Feily
Reza
R
Yaghoobi
D000818:Animals; D056587:Cryopyrin-Associated Periodic Syndromes / Q000188:drug therapy; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D019873:Schnitzler Syndrome / Q000188:drug therapy; D015595:Skin Aging / Q000187:drug effects; D012871:Skin Diseases / Q000188:drug therapy*
D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1